Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.
about
Febuxostat for treating chronic gout2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaEltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisalSafety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.Efficacy and safety of febuxostat in patients with hyperuricemia and gout.Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysisMultinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal.Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal.Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.Cost-effectiveness of febuxostat in chronic gout.
P2860
Q24202984-4B46472A-276B-4FCE-97BA-B8DBF859184CQ24612292-74455DAE-D42B-4BE5-84DC-D8FE4A2419F4Q33400612-6A68CFEC-993A-4B08-9A1E-8BA694ADB92EQ34573847-BB0D8AAF-8F23-45CA-ABDA-CBCEE3AA2241Q35528880-CCFE2462-A9E2-426C-9C1D-3CE9E5459333Q36059557-CA329F0D-0FDE-4D07-A7AD-63F56B013F79Q36844535-27E27069-A7C6-4FBF-9CE7-851F6BBB2941Q37312451-9785B0EA-BDEB-4275-B42E-7D47CE04D5DCQ37553140-0220F05D-09DE-4805-A607-03800D2F590AQ37919866-71C6DD2E-BB43-4AD6-9666-0A78ED0A30EAQ37941769-5DDA7A67-9348-4538-8BB0-D3620ADF7FCCQ37963977-C2480F40-A072-4661-AE30-BF2F84C6E931Q37970113-15B27210-6AEC-4D2A-9010-BFB6921FC1AAQ37979273-55B62B9A-67E3-449A-B77F-087DCEECD8B5Q38040848-30DBBA9F-72B1-42D3-A9FF-98C29CFB404FQ38051449-548CD9E3-8191-441A-BDE2-4F5C4113FC05Q38074913-AD73FCDB-A4D1-437B-8E5F-0937E76F017CQ38076077-7ED3B163-3868-4A6D-AB29-44B006F33E78Q38078288-6FFF8B1F-D6D1-45AB-98A9-56C9E56EC61DQ38091324-DFED5466-F446-4041-A988-E4064F3E8FECQ38097338-433CAD4D-3504-46BA-8896-A85198D36EA6Q38098104-A87E80CF-286E-4610-A331-DB7FA4EC5152Q38098483-430E77E2-D5CF-4E59-BE71-AEF5EE6A2957Q38098484-D0CD694E-03C9-490D-ACC8-17D97A5D2173Q38101892-CC1E6771-EF60-45D6-BDEE-AE4EABD38985Q38133381-BD181642-E7DD-48B7-90D1-F278B1953F9AQ38149091-00105400-BBBC-49E7-ADBC-971721F8F3EDQ46847933-0FF5E68F-9977-49A8-BEA5-73059AEEB57B
P2860
Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Febuxostat for the management ...... E single technology appraisal.
@en
Febuxostat for the management ...... E single technology appraisal.
@nl
type
label
Febuxostat for the management ...... E single technology appraisal.
@en
Febuxostat for the management ...... E single technology appraisal.
@nl
prefLabel
Febuxostat for the management ...... E single technology appraisal.
@en
Febuxostat for the management ...... E single technology appraisal.
@nl
P2860
P1433
P1476
Febuxostat for the management ...... E single technology appraisal.
@en
P2093
Matt Stevenson
P2860
P304
P356
10.2165/11535770-000000000-00000
P577
2011-02-01T00:00:00Z
P5875
P6179
1001950861